AXL-associated tumor inflammation as a poor prognostic signature in chemotherapy-treated triple-negative breast cancer patients.

Cox multivariate regression analysis, adjusted for age at diagnosis, histological grade, lymph node status, tumor size, and tumor stage, demonstrated that only AXL expression remained an independent poor prognostic factor for RFS and OS in TNBC patients treated with adjuvant chemotherapy, along with lymph node status, whereas CD163 only retained a positive trend for reduced RFS ( Table 2 ).

also in 11,005 other papers